Ratings by William Blair (Tim Lugo)
Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
3/28/2024 | Solid Biosciences | SLDB | New Coverage | Outperform (N/A) |
14.25 (13.32) |
-6.53% | Details | |
3/12/2024 | Zevra Therapeutics, Inc. | ZVRA | New Coverage | Outperform (N/A) |
6.13 (5.80) |
-5.38% | Details | |
2/20/2024 | ARS Pharmaceuticals Inc | SPRY | Upgrade | Outperform (Market Perform) |
7.17 (10.22) |
42.54% | Details | |
2/16/2024 | Kinnate Biopharma | KNTE | Downgrade | Market Perform (Outperform) |
2.27 (2.66) |
17.18% | Details | |
1/29/2024 | Abbvie | ABBV | Upgrade | Outperform (Market Perform) |
164.40 (182.10) |
10.77% | Details | |
12/20/2023 | argenx SE | ARGX | Downgrade | Market Perform (Outperform) |
452.58 (393.72) |
-13.01% | Details | |
12/18/2023 | Allakos Inc. | ALLK | Upgrade | Outperform (Market Perform) |
3.00 (1.26) |
-58% | Details | |
11/13/2023 | Aclaris Therapeutis | ACRS | Downgrade | Market Perform (Outperform) |
4.76 (1.24) |
-73.95% | Details | |
11/1/2023 | Eyenovia | EYEN | New Coverage | Outperform (N/A) |
1.30 (0.99) |
-23.85% | Details | |
9/21/2023 | Travere Therapeutics | TVTX | Downgrade | Market Perform (Outperform) |
12.88 (7.71) |
-40.14% | Details | |
9/20/2023 | ARS Pharmaceuticals Inc | SPRY | Downgrade | Market Perform (Outperform) |
7.44 (10.22) |
37.37% | Details | |
7/25/2023 | Abbvie | ABBV | New Coverage | Market Perform (N/A) |
143.18 (182.10) |
27.18% | Details | |
5/24/2023 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
5/10/2023 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
1/3/2023 | ARS Pharmaceuticals Inc | SPRY | New Coverage | Outperform (N/A) |
8.53 (10.22) |
19.81% | Details | |
9/9/2022 | Allakos Inc. | ALLK | Maintain | Market Perform (N/A) |
|
Details | ||
9/8/2022 | Revance Therapeutic | RVNC | Maintain | Outperform (N/A) |
|
Details | ||
8/3/2022 | Sarepta Therapeutics | SRPT | Maintain | Outperform (Outperform) |
|
Details | ||
7/22/2022 | VistaGen Therapeutics | VTGN | Downgrade | Market Perform (Outperform) |
1.07 (5.28) |
393.46% | Details | |
7/22/2022 | VistaGen Therapeutics | VTGN | Downgrade | Market Perform (Outperform) |
1.07 (1.07) |
0% | Details | |
7/13/2022 | Xenon Pharmaceuticals | XENE | Maintain | Outperform (Outperform) |
|
Details | ||
7/13/2022 | 9 Meter Biopharma | NMTR | Maintain | Outperform (Outperform) |
|
Details | ||
7/13/2022 | VistaGen Therapeutics | VTGN | Maintain | Outperform (Outperform) |
|
Details | ||
6/24/2022 | Sarepta Therapeutics | SRPT | Maintain | Outperform (Outperform) |
|
Details | ||
6/23/2022 | Xenon Pharmaceuticals | XENE | Maintain | Outperform (Outperform) |
|
Details | ||
6/8/2022 | VistaGen Therapeutics | VTGN | Maintain | Outperform (Outperform) |
|
Details | ||
6/8/2022 | Albireo Pharma | ALBO | Maintain | Outperform (Outperform) |
|
Details | ||
5/26/2022 | VistaGen Therapeutics | VTGN | Maintain | Outperform (Outperform) |
|
Details | ||
5/23/2022 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (Outperform) |
|
Details | ||
5/4/2022 | Brickell Biotech Inc. | BBI | Maintain | Outperform (Outperform) |
|
Details | ||
4/5/2022 | Collegium Pharmaceutical | COLL | Maintain | Outperform (Outperform) |
|
Details | ||
4/4/2022 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (Outperform) |
|
Details | ||
3/29/2022 | Kinnate Biopharma | KNTE | Maintain | Outperform (Outperform) |
|
Details | ||
3/28/2022 | Eagle Pharmaceuticals | EGRX | Maintain | Outperform (Outperform) |
|
Details | ||
3/23/2022 | 9 Meter Biopharma | NMTR | Maintain | Outperform (Outperform) |
|
Details | ||
3/15/2022 | Brickell Biotech Inc. | BBI | Maintain | Outperform (Outperform) |
|
Details | ||
3/9/2022 | Lyra Therapeutics | LYRA | Maintain | Outperform (Outperform) |
|
Details | ||
3/8/2022 | Revance Therapeutic | RVNC | Maintain | Outperform (Outperform) |
|
Details | ||
3/8/2022 | Brickell Biotech Inc. | BBI | New Coverage | Outperform (N/A) |
0.20 (2.35) |
1075% | Details | |
3/2/2022 | Allakos Inc. | ALLK | Maintain | Market Perform (Market Perform) |
|
Details | ||
3/1/2022 | Albireo Pharma | ALBO | Maintain | Outperform (Outperform) |
|
Details | ||
2/25/2022 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (Outperform) |
|
Details | ||
2/16/2022 | Allakos Inc. | ALLK | Maintain | Market Perform (Market Perform) |
|
Details | ||
2/11/2022 | VistaGen Therapeutics | VTGN | Maintain | Outperform (Outperform) |
|
Details | ||
1/19/2022 | Zogenix, Inc. | ZGNX | Downgrade | Market Perform (Outperform) |
15.64 (26.68) |
70.59% | Details | |
1/19/2022 | Revance Therapeutic | RVNC | Maintain | Outperform (Outperform) |
|
Details | ||
12/22/2021 | Allakos Inc. | ALLK | Downgrade | Market Perform (Outperform) |
84.39 (1.26) |
-98.51% | Details | |
11/9/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
10/19/2021 | Atea Pharmaceuticals | AVIR | Maintain | Outperform (N/A) |
|
Details | ||
10/11/2021 | Adamas Pharmaceuticals | ADMS | Downgrade | Market Perform (Outperform) |
4.61 (8.22) |
78.31% | Details | |
8/31/2021 | Eagle Pharmaceuticals | EGRX | Maintain | Outperform (N/A) |
|
Details | ||
7/13/2021 | Kinnate Biopharma | KNTE | New Coverage | Outperform (N/A) |
22.61 (2.27) |
-89.96% | Details | |
6/15/2021 | Sage Therapeutics | SAGE | Downgrade | Market Perform (Outperform) |
72.86 (18.74) |
-74.28% | Details | |
1/4/2021 | VistaGen Therapeutics | VTGN | Upgrade | Outperform (Market Perform) |
1.94 (5.28) |
172.16% | Details | |
11/24/2020 | Atea Pharmaceuticals | AVIR | New Coverage | Outperform (N/A) |
33.54 (4.04) |
-87.95% | Details | |
9/23/2020 | 9 Meter Biopharma | NMTR | New Coverage | Outperform (N/A) |
0.69 (0.07) |
-89.86% | Details | |
6/26/2020 | Zogenix, Inc. | ZGNX | Maintain | Outperform (N/A) |
|
Details | ||
6/5/2020 | Adamas Pharmaceuticals | ADMS | Maintain | Outperform (N/A) |
|
Details | ||
6/3/2020 | BVHN | Maintain | Outperform (N/A) |
|
Details | |||
5/26/2020 | Lyra Therapeutics | LYRA | New Coverage | Outperform (N/A) |
14.43 (6.22) |
-56.9% | Details | |
2/3/2020 | Agile Therapeutics | AGRX | Maintain | Outperform (N/A) |
|
Details | ||
1/8/2020 | Xenon Pharmaceuticals | XENE | New Coverage | Outperform (N/A) |
14.73 (43.05) |
192.26% | Details | |
12/10/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
11/14/2019 | VistaGen Therapeutics | VTGN | Downgrade | Market Perform (Outperform) |
1.08 (5.28) |
388.89% | Details | |
10/31/2019 | argenx SE | ARGX | Upgrade | Outperform (Market Perform) |
119.14 (393.72) |
230.47% | Details | |
9/17/2019 | Collegium Pharmaceutical | COLL | Maintain | Outperform (N/A) |
|
Details | ||
8/28/2019 | VistaGen Therapeutics | VTGN | New Coverage | Outperform (N/A) |
0.64 (1.08) |
68.75% | Details | |
6/25/2019 | Acer Therapeutics | ACER | Downgrade | Market Perform (Outperform) |
19.28 (0.90) |
-95.33% | Details | |
12/20/2018 | Shire | SHPG | Downgrade | Market Perform (Outperform) |
168.73 (179.20) |
6.21% | Details | |
8/13/2018 | Allakos Inc. | ALLK | New Coverage | Outperform (N/A) |
37.27 (1.26) |
-96.62% | Details |